Phase 1
Completed N=13
Single Doses of MK-0941 in Type 2 Diabetics (MK-0941-027)
Source: ClinicalTrials.gov NCT01106287 ↗Enrolled (actual)
13
Serious AEs
0.0%
Results posted
Dec 2012
Primary outcomePrimary: Number of Participants Who Experienced One or More Adverse Events During the Study — 2; 6; 4; 9 participants
Summary
This study will evaluate the safety and tolerability of single doses of MK-0941 based on assessment of clinical and laboratory adverse experiences
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants Who Experienced One or More Adverse Events During the Study |
2; 6; 4; 9; 4; 5 | — |
| PRIMARY Number of Participants Who Discontinued Study Drug Due to an Adverse Event |
0; 0; 0; 0; 0; 0 | — |
Eligibility Criteria
Inclusion Criteria
- Female participants of reproductive potential must test negative for pregnancy and agree to use two acceptable methods of birth control
- Diagnosis of Type 2 Diabetes and is either being treated with diet and exercise alone or with a single or combination oral anti-hyperglycemic agent
- No treatment with three of more anti-hyperglycemic agents or any treatment regimen that includes insulin
- In good health (except for Type 2 Diabetes)
- Willingness to follow a specific diet throughout the study (consisting of 50% carbohydrates, 20%protein and 30% fat)
- Nonsmoker
Exclusion Criteria
- History of stroke, chronic seizure or major neurological disorder
- History of cancer
- History of Type 1 Diabetes
- Recent history of eye infection
- Glaucoma or blindness
- Eye surgery (by incision or laser) within the past three months
Data sourced from ClinicalTrials.gov (NCT01106287). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.